Literature DB >> 29305306

Filovirus proteins for antiviral drug discovery: Structure/function of proteins involved in assembly and budding.

Baptiste Martin1, Olivier Reynard2, Viktor Volchkov3, Etienne Decroly4.   

Abstract

There are no approved medications for the treatment of Marburg or Ebola virus infection. In two previous articles (Martin et al., 2016, Martin et al., 2017), we reviewed surface glycoprotein and replication proteins structure/function relationship to decipher the molecular mechanisms of filovirus life cycle and identify antiviral strategies. In the present article, we recapitulate knowledge about the viral proteins involved in filovirus assembly and budding. First we describe the structural data available for viral proteins associated with virus assembly and virion egress and then, we integrate the structural features of these proteins in the functional context of the viral replication cycle. Finally, we summarize recent advances in the development of innovative antiviral strategies to target filovirus assembly and egress. The development of such prophylactic or post-exposure treatments could help controlling future filovirus outbreaks.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral therapy; Ebola virus; Filovirus; Marburg virus; Mononegavirales; Virion assembly

Mesh:

Substances:

Year:  2018        PMID: 29305306     DOI: 10.1016/j.antiviral.2017.12.022

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads.

Authors:  Manu Anantpadma; Thomas Lane; Kimberley M Zorn; Mary A Lingerfelt; Alex M Clark; Joel S Freundlich; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  ACS Omega       Date:  2019-01-30

2.  Ebola Virus VP40 Modulates Cell Cycle and Biogenesis of Extracellular Vesicles.

Authors:  Michelle L Pleet; James Erickson; Catherine DeMarino; Robert A Barclay; Maria Cowen; Benjamin Lepene; Janie Liang; Jens H Kuhn; Laura Prugar; Spencer W Stonier; John M Dye; Weidong Zhou; Lance A Liotta; M Javad Aman; Fatah Kashanchi
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 3.  Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion.

Authors:  Michelle L Pleet; Catherine DeMarino; Spencer W Stonier; John M Dye; Steven Jacobson; M Javad Aman; Fatah Kashanchi
Journal:  Viruses       Date:  2019-05-02       Impact factor: 5.048

4.  Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Manu Anantpadma; Joel S Freundlich; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  PLoS Negl Trop Dis       Date:  2019-11-21

5.  An Investigation of the Effect of Transfected Defective, Ebola Virus Genomes on Ebola Replication.

Authors:  Sophie J Smither; Isabel Garcia-Dorival; Lin Eastaugh; James S Findlay; Lyn M O'Brien; Jonathan Carruthers; E Diane Williamson; Carmen Molina-París; Julian A Hiscox; Thomas R Laws
Journal:  Front Cell Infect Microbiol       Date:  2020-04-21       Impact factor: 5.293

6.  The Minor Matrix Protein VP24 from Ebola Virus Lacks Direct Lipid-Binding Properties.

Authors:  Yuan Su; Robert V Stahelin
Journal:  Viruses       Date:  2020-08-08       Impact factor: 5.048

7.  Ubiquitin Ligase SMURF2 Interacts with Filovirus VP40 and Promotes Egress of VP40 VLPs.

Authors:  Ariel Shepley-McTaggart; Michael Patrick Schwoerer; Cari A Sagum; Mark T Bedford; Chaitanya K Jaladanki; Hao Fan; Joel Cassel; Ronald N Harty
Journal:  Viruses       Date:  2021-02-12       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.